World Journal of Gastrointestinal Pharmacology and Therapeutics

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Ellington AL, Rambuss D, Barbina S, Chitnavis M. Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study. World J Gastrointest Pharmacol Ther 2026; 17(2): 120059 [PMID: 42273244 DOI: 10.4292/wjgpt.v17.i2.120059]
URL:	https://www.wjgnet.com/2150-5349/full/v17/i2/120059.htm

(32) (30) (0) (0) (0) (1) (875) (1)

Number	Citing Articles
1	Himanshu Agrawal, Nikhil Gupta. Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2026; 17(3): 122912 doi: 10.4292/wjgpt.122912 Abstract(14) \| Core Tip(12) \| Full Article(HTML)(40) \| Full Article (PDF)-369K(6) \| Full Article with Cover (PDF)-706K(5) \| Full Article (XML)-45K(6) \| Audio-125K(1) \| Peer-Review Report-334K(9) \| Answering Reviewers-71K(9) \| Times Cited (0) \| Total Visits (57) \| Open

Number

Citing Articles

Himanshu Agrawal, Nikhil Gupta. Letter to the Editor: Can upadacitinib dose escalation redefine treatment strategies in refractory inflammatory bowel disease?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2026; 17(3): 122912 doi: 10.4292/wjgpt.122912

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.